Slide 1: Where Technology Comes to Life
WHERE TECHNOLOGY COMES TO LIFE Q3 2025
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains forward-looking statements within the Israeli Securities Law, 1968, the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws, as amended, regarding Pluri Inc. and/or its subsidiaries (collectively the “Company” o
Slide 3: Pluri Venture Creation
Pluri Venture Creation Company Sectors Partners Regenerative ~$22 million (as of Medicine June 30, 2025) Cultivated Meat ~ Contract Development and Manufacturing Organization Cell-Based Agriculture
Slide 4: From Single Cells To Sustainable Solutions
From Single Cells To Sustainable Solutions Pluri harnesses the power of cells, the building blocks of life, to deliver eco-friendly solutions that aim to enhance individual well-being and drive positive global change Pluri leverages two decades of experience and proprietary platform for cell-based s
Slide 5: Eight Billion Lives. One Planet. Zero Time to Waste.
Eight Billion Lives. One Planet. Zero Time to Waste. Aging and Health Climate Change Food Security Sustainability A growing, aging world urgently needs scalable, sustainable solutions
Slide 6: Pluri Technological Platform
Pluri Technological Platform Innovative Validated
Slide 7: Bio-Farming: Industrial Scale Production
Bio-Farming: Industrial Scale Production PluriMatrix
Slide 8: Cell-based Technology Platform
AgTech CDMO Funded POCs with Acute Radiation ICL and others Significant source of income, • $2.2M funded by U.S. gov annual growth rate >50% • Collab with Hemafund Cultivated cacao Osteoarthritis €7.5M funding for PROTO consortium 71% ownership Cultivated Cell-based Coffee Technology Platform Immuno
Slide 9: A Clear Path to Venture Creation
A Clear Path to Venture Creation Feasibility & de-risking Model options Ventures Coffeesai 1. Ideation and market assessment Subsidiaries Kokomodo 2. Partner collaboration for PluriCDMO need validation 3. Team recruitment Ever After Foods 4. POC Funding and validation Joint-Venture PROTO 5. Corporat
Slide 10: Pluri Establishes a Collaborative Network of Ventures
Pluri Establishes a Collaborative Network of Ventures IP Improvements Registration of new patents and improvement of existing patents for various industries such as pharmaceuticals, food, and agriculture Shared Shared Facilities and Network Know-how of Partners Innovative GMP-certified Encouraging c
Slide 11: Joint Ventures
Joint Ventures
Slide 12: Growing the Future of Food with Cultivated Meat
Growing the Future of Food with Cultivated Meat Ever After Foods leverages Pluri’s cell expansion technology to produce mass scale, cost-effective food products in an efficient and sustainable manner, aiming to solve the industry’s scalability challenges Environmental Ethical Consumer ● Less land an
Slide 13: Ever After Foods Milestones
Ever After Foods Milestones • Tnuva $7.5 million according to a $40 million pre- money valuation • Pluri granted exclusive global royalty-bearing license to use its IP and expertise
Slide 14: Subsidiaries
Subsidiaries
Slide 15: Reimagining Coffee Without Ecological Cost
Reimagining Coffee Without Ecological Cost Climate Change Land Shortage decrease reduce Price Instability Carbon Footprint risen water
Slide 16: A Consistent Methodology for Rapid, De-risked Venture Creation
A Consistent Methodology for Rapid, De-risked Venture Creation
Slide 17: The Coffeesai Solution uses 100% Real Coffee
The Coffeesai Solution uses 100% Real Coffee Drying Roasting Brewing
Slide 18: Cacao at risk due to climate change
Cacao at risk due to climate change Unstable supply Rising prices Complex supply chain Cocoa market growth Inconsistent quality
Slide 19: Kokomodo milestones
Kokomodo milestones Feb. 2024 H2 2025 kokomodo Cultivating Cocoa’s Future 2026 Company founded by Plantae Bioscience, The Kitchen (a Strauss Group company), and Tal Goverin. An investment of approximately 2.5 million NIS was made for initial feasibility by Pluri “8 ~71% ownership POC deals with glob
Slide 20: Out Licensing
Out Licensing
Slide 21: PLX-R18 for Acute Radiation Syndrome
PLX-R18 for Acute Radiation Syndrome Studies and Collaborations Survival Rate • The U.S. National Institutes of Health (NIH) and the Department of Defense (DoD) funded $2.2 million out of the total $4.2 million budget Significant increase (68%) vs placebo (p<0.0001) originally allocated for the stud
Slide 22: Pluri's Recent Achievements
Pluri’s Recent Achievements €7.5M Consolidated Launch of cell- Launch of cash balance Collaboration based coffee CDMO $22M (as of with Charite business business June 30, 2025) Berlin $10M strategic Cultivated meat Collaborations Launch of investment and Coffeesai to Growth in revenues PROTO: Phase I
Slide 23: Science in Service of Humanity
Science in Service of Humanity Pluri is a global leader in cell technology, aiming to deliver cell-based solutions with a goal to improve global well-being and drive sustainability in multiple sectors
Slide 24: Our Collaborative Network of Partnerships
Our Collaborative Network of Partnerships Regulatory Scientific Collaborations Funding and Partnering
Slide 25: Our Team
Our Team Yaky Yanay Liat Zalts Lior Raviv Dr. Michal Sheleg, PhD Nimrod Bar Zvi CEO & President Chief Financial Officer Chief Technology Officer VP Clinical Development Chief Commercial Officer Dr. Arthur Machlenkin, PhD Nofar Glaich-Dabach Orly Amiran Efrat Kaduri Ori Shalem Chief Scientific Office
Slide 26: Thank You
THANK YOU. Our cell-based innovations are aimed at transforming industries with a goal to create a more sustainable, healthier world. From the food we eat to the medicine we consume, we are building solutions that can potentially serve humanity, one breakthrough at a time. For further info: investor